Aptiv PLC (APTV) Q1 2025 Earnings Call Highlights: Record EPS Amid Revenue Challenges
Revenue: $4.8 billion, down 1% year-over-year.
Operating Income: $572 million, an increase of over 5%.
Earnings Per Share (EPS): $1.69, a first quarter record.
Operating Cash Flow: $273 million.
Share Repurchase Program: Completed $3 billion program, reducing share count by 18%.
Bookings: Nearly $5 billion in the first quarter.
Advanced Safety and User Experience Revenue: Flat, with active safety revenues up 9%.
Engineered Components Group Revenue: Increased 1%, with China revenues up 24%.
Electrical Distribution Systems Revenue: Declined 3%.
Adjusted EBITDA: $758 million.
Operating Income Margin: Expanded 80 basis points year-over-year.
Capital Expenditures: $197 million in the quarter.
Second Quarter Revenue Guidance: $4.92 billion to $5.12 billion.
Second Quarter Operating Income Guidance: $575 million at the midpoint.
Second Quarter EPS Guidance: $1.80 at the midpoint.
Debt Reduction: Paid down approximately $700 million of debt since the start of the year.
Liquidity: Over $3.4 billion with net leverage at 2.2 times.
Warning! GuruFocus has detected 3 Warning Sign with APTV.
Release Date: May 01, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Aptiv PLC (NYSE:APTV) exceeded its first-quarter guidance due to higher vehicle production volumes, particularly in China, and strong growth in non-automotive markets.
Operating income reached a record $572 million, reflecting a 5% increase due to strong operating execution and cost reduction initiatives.
The company completed a $3 billion accelerated share repurchase program, reducing its share count by 18% and enhancing shareholder value.
Aptiv PLC (NYSE:APTV) secured nearly $5 billion in new business awards, with significant traction in China, including $1.4 billion in bookings with local OEMs.
The company announced strategic partnerships with ServiceNow and Capgemini to expand its cloud solutions, enhancing its footprint in the enterprise sector.
Revenue declined by 1% to $4.8 billion due to lower vehicle production in North America and Europe, and negative customer mix.
The company faces uncertainty due to rapid changes in global trade policies, impacting demand in the automotive market.
Aptiv PLC (NYSE:APTV) is experiencing delays in customer program awards due to trade policy and regulatory changes.
The Electrical Distribution Systems (EDS) segment saw a 3% revenue decline, primarily due to lower light vehicle production.
The company is cautious about the second half of the year due to uncertain vehicle production volumes and consumer demand.
Q: Kevin, can you clarify the outlook for the second quarter and the second half of the year, particularly regarding tariffs and production volumes? A: Kevin Clark, CEO: For the second quarter, we have visibility into production schedules and have accounted for tariff impacts. The uncertainty lies in the second half, primarily concerning vehicle production volumes, which depend on consumer demand and OEM pricing strategies. We are managing tariff impacts and will pass any unmitigated costs to customers.
Q: Can you provide more details on the potential relocation of high-value production to the US? A: Kevin Clark, CEO: It's early days, but this would not include the wire harness business. We are considering moving parts of our ASUX or ECG business that can be highly automated. We would initially leverage our existing US manufacturing footprint, but no specific capital investment details are available yet.
Q: How is the macro uncertainty affecting advanced content bidding and launches? A: Kevin Clark, CEO: The activity level remains robust, but OEMs are taking longer to finalize paths and award contracts. This delay is similar to last year, where awards were stronger in the back half. Engagement with OEMs is at high levels.
Q: Does the macro uncertainty or the heavy footprint in Mexico affect the EDS spin-off plan? A: Kevin Clark, CEO: The plan to separate the EDS business remains unchanged. Our focus is on growing the business, standardizing wire harnesses, and expanding beyond automotive. The separation will allow EDS to pursue these goals more effectively.
Q: Can you explain the volume decline implied in the guidance for the second half and how it compares to third-party forecasts? A: Kevin Clark, CEO: We rely on customer schedules rather than third-party forecasts like IHS. Our guidance framework is based on initial assumptions and provides a baseline for vehicle production scenarios. The focus is on volume uncertainty in the second half, not direct tariff impacts.
Q: How did you arrive at the assumption for 4% lower production in Q2, and how are tariffs affecting this? A: Kevin Clark, CEO: Our forecast is based on customer production schedules, which are reliable closer to production dates. We haven't seen significant schedule changes due to tariffs, and current schedules align with our February expectations, with minor OEM and platform adjustments.
Q: Can you elaborate on the strong Q1 EBITDA margin and the expected margin walk from Q1 to Q2? A: Varun Laroyia, CFO: Q1 margins benefited from strong operational performance, strategic sourcing, and volume flow-through. For Q2, ongoing operational activities continue, but FX and commodity headwinds, particularly related to the Mexican peso, will impact margins.
Q: How should we interpret the tariff commentary regarding USMCA compliance and potential risks? A: Kevin Clark, CEO: With over 99% of our US-Mexico trade flows being USMCA compliant, our exposure is minimal. The main risk would be a shift to a US sourcing rule, but current guidance suggests this is unlikely.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
3 Top Stocks Yielding Over 3% to Buy Right Now for Dividend Income and Upside Potential
Brookfield Infrastructure has increased its high-yielding payout every year since its formation. PepsiCo is an elite dividend stock. Prologis is growing its dividend much faster than the average dividend stock. 10 stocks we like better than PepsiCo › Dividend-paying stocks can be great investments. They can enable you to generate some passive income, providing a real return. In addition, dividend stocks have historically produced strong total returns as they've grown their earnings and shareholder payouts, driving stock price appreciation. Brookfield Infrastructure (NYSE: BIPC)(NYSE: BIP), PepsiCo (NASDAQ: PEP), and Prologis (NYSE: PLD) currently stand out among dividend stocks. The trio has excellent records of paying growing dividends. On top of that, they currently offer attractive yields of more than 3%, partly due to drops in their stock prices this year. Because of that, they offer compelling blends of dividend income and upside potential. Shares of Brookfield Infrastructure have declined by nearly 10% from their 52-week high. That slump has pushed the global infrastructure company's dividend yield up to 4.2%. The company's stock price has also slumped, even though it's having another good year, and its funds from operations (FFO) rose 5% in the first quarter, powered by inflation-driven rate increases, recently completed expansion projects, and acquisitions closed in the past year. Brookfield Infrastructure has a terrific record of paying dividends. It has increased its payment in all 16 years since its formation, growing it at a 9% compound annual rate. The company expects to continue increasing its payout in the future, targeting 5% to 9% annual growth. It sees a trio of organic growth drivers (inflation-driven rate increases, volume growth as the global economy expands, and expansion projects), increasing its FFO per share by 6% to 9% per year. On top of that, the company has an excellent record of making accretive acquisitions funded by recycling capital. It recently agreed to invest $500 million in the acquisition of Colonial Enterprises, which owns a leading U.S. refined products pipeline system. It also partnered with GATX Corporation to buy Wells Fargo's rail operating lease portfolio (consisting of 105,000 railcars) for $4.4 billion. It's also acquiring Wells Fargo's rail finance lease portfolio (23,000 railcars and 440 locomotives) in a separate deal. Brookfield estimates that acquisitions like these will help push its FFO growth rate above 10% annually. PepsiCo stock has slumped more than 25% from its 52-week high. That plunge has propelled its dividend yield to 4.4%. That's a tasty level for a company with a long history of satisfying investors' cravings for more dividend income. The food and beverage giant recently increased its dividend payment by another 5%. That extended its growth streak to 53 straight years, enough to qualify PepsiCo as an elite Dividend King. PepsiCo's stock is down due to concerns that tariffs, a slowing economy, and changing consumer tastes will impact the company's growth. On the one hand, the company is seeing some impact from those headwinds this year. It now expects its earnings per share to be at the same level as last year's, compared to the mid-single-digit growth rate it initially expected. However, the company has a resilient business and expects its growth to reaccelerate in the coming years. It has been investing heavily in the strategic transformation of its portfolio to healthier food and beverage options, including buying Poppi, Siete, and Sabra in recent quarters. These investments should pay dividends for the company in the coming years by reigniting its earnings growth engine, which should enable PepsiCo to continue increasing its dividend. Prologis stock has slumped more than 15% this year. That sell-off has helped nudge its dividend yield up to 3.7%. The leading industrial real estate investment trust (REIT) has been under some pressure due to slowing demand for warehouse space. However, the company is still performing well amid all the uncertainty. Its core FFO per share increased 11% in the first quarter as it continues to sign new leases at much higher rates compared to the price point of expiring contracts on the same space. Meanwhile, the long-term demand picture for warehouse space remains robust. "Over the long term, limited new supply and high construction costs support continued rent growth," commented CEO and co-founder Hamid Moghadam in the first-quarter earnings press release. That should enable the company to capture higher rental rates on its existing properties and continue developing new warehouses. In addition, Prologis is using some of its land to build data centers to capitalize on the growing demand for these properties to support increased digitalization and AI technology. Prologis' growth prospects should enable the REIT to continue increasing its dividend. It has grown its payout at a 13% compound annual rate over the past five years. That's faster than the S&P 500 (5%) and REIT sector average (6%). Brookfield Infrastructure, PepsiCo, and Prologis offer investors the best of both worlds. They pay dividends that yield more than double the S&P 500's average (less than 1.5%), and they have compelling upside potential from their earnings growth and an eventual recovery in their stock prices. Because of that, they could produce strong total returns from here, making them great dividend stocks to buy right now. Before you buy stock in PepsiCo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and PepsiCo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Wells Fargo is an advertising partner of Motley Fool Money. Matt DiLallo has positions in Brookfield Infrastructure, Brookfield Infrastructure Partners, PepsiCo, and Prologis. The Motley Fool has positions in and recommends Prologis. The Motley Fool recommends Brookfield Infrastructure Partners and recommends the following options: long January 2026 $90 calls on Prologis. The Motley Fool has a disclosure policy. 3 Top Stocks Yielding Over 3% to Buy Right Now for Dividend Income and Upside Potential was originally published by The Motley Fool
Associated Press
3 hours ago
- Associated Press
Lead Plaintiff Deadline is June 16, 2025 for Investors of Ibotta, Inc.
NEW YORK, NY - June 8, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ibotta, Inc. ('Ibotta' or the 'Company') (NYSE: IBTA) on behalf of Ibotta investors. CLICK HERE TO JOIN THE CASE If you are an investor in Ibotta and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than June 16, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. Ibotta purports to be a technology company that allows consumer packaged goods brands to deliver digital promotions to consumers through the Ibotta Performance Network. On April 18, 2024, Ibotta conducted its Initial Public Offering ('IPO'), offering 6,560,700 million shares of Class A common stock at a price of $88 per share. The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that; (i) Ibotta's data measurement system did not provide accurate, precise, and real time client campaign and consumer data measurement; (ii) the Company's business mix had shifted and was generating less revenue; and (iii) Ibotta had 'exhausted' its clients' budgets, negatively impacting fourth quarter 2024 revenue and expected first quarter 2025 revenue. According to the action, on February 26, 2025, after market hours, in connection with reporting fourth quarter 2024 and full year 2024 financial results, Ibotta's CEO Bryan W. Leach ('CEO Leach') explained just how deficient Ibotta's data measurement technology was by stating that 'it has become clear that we need to bring to market a more rigorous form of measurement that goes beyond the industry standard return on ad spend, or ROAS, framework.' Further CEO Leach allegedly announced that Ibotta would transform into a programmatic advertising company, which according to the complaint demonstrates that, at the time of the IPO, Ibotta's data measurement infrastructure was not suited for heavy reliance on third party platforms. On this news, the price of Ibotta's stock fell $29.08, or nearly 46%, to close at $34.09 on February 27, 2025, more than 60% lower than the IPO price of $88 per share. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. View the original release on
Yahoo
5 hours ago
- Yahoo
This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space
Hims & Hers is gaining market share in the telehealth sector and has a long runway to disrupt the healthcare industry. It is acquiring a company in order to enter Europe. The stock is expensive, but it may still be a great investment over the long term. 10 stocks we like better than Hims & Hers Health › Telehealth has gone through a major boom-and-bust cycle. One promising stock emerging from the bust is Hims & Hers (NYSE: HIMS). Through nifty marketing and an insurance-circumventing subscription model that delivers medicine directly to your front door, the company is taking a lot of share in the telehealth market. The stock has traded up 449% since going public, and it is up a staggering 158% in the past year. Disruptive innovation helped bring shareholders of Hims & Hers stock major gains. But does that make the stock a buy today? People in the United States get frustrated dealing with health insurance -- as you may know from personal experience. Hims & Hers aims to slowly disrupt the market with an innovative approach that bypasses insurers. It helps customers easily get generic medications that help deal with sexual health, hair loss, mental health, and other common concerns, by having prescriptions and shipments sent straight to their doors through monthly subscriptions. This model has helped Hims & Hers dominate the telehealth prescription market and reach $1.78 billion in trailing-12-month revenue. It's now trying to further expand its offerings by adding the branded weight loss drug Wegovy to its marketplace through a partnership with Novo Nordisk (NYSE: NVO). Previously, Hims & Hers sold weight loss drugs under an exemption because of supply shortages for the products, but with those shortages now resolved, it has to work with patent holders such as Novo Nordisk. Along with weight loss, it's also aiming to get into testosterone and menopause-related prescriptions. Today, Hims & Hers has 2.4 million active customers. Management believes there are over 100 million people who could utilize one of its products, giving the company a huge runway to grow. A key factor will be the new partnership for marketing Wegovy, which is an expensive subscription at an introductory discount offer of $549 a month. Usage of such drugs is growing like a weed, and could be a new growth avenue for Hims & Hers to pursue. Another huge step for Hims & Hers is international expansion. While countries vary in their approaches to healthcare and insurance, most people want easy-to-use products, affordable prices, and convenient at-home shipping regardless of where they live. Management hopes to supercharge international growth with its proposed buyout of competitor Zava in Europe. Zava serves the western European market with 1.3 million active customers in the United Kingdom, France, Germany, and Ireland. The combined company can utilize Hims & Hers' marketing expertise, increasing scale, and partnerships to bring this sought-after model to Europe. Global disruption of the healthcare space will give Hims & Hers an even larger runway for growth, while also allowing it to invest in new innovations -- including at-home patient testing and its own compounding manufacturing facility. Hims & Hers has grand ambitions to disrupt healthcare with its direct-to-consumer model, and Zava will give it even more scale to keep accelerating growth. It will be exciting to see what the combined company can do over the next decade. You can feel the excitement with Hims & Hers and its explosive revenue growth. Sales grew 111% year over year last quarter, and are expected to hit at least $2.3 billion in 2025. (They were just $100 million in 2020.) The company has a goal of reaching $6.5 billion in sales by 2030, which would make it one of the fastest-growing companies in the world this decade. This fast growth has created some high expectations for Hims & Hers stock. It now has a price-to-earnings ratio (P/E) of 79, which is a high trailing earnings multiple even for a fast-growing company. However, revenue is growing so quickly and with such high margins that the company may grow into this high valuation by the end of the decade. As noted, management has a goal of $6.5 billion in revenue in 2030. With 20% bottom-line profit margins -- easily doable with 77% gross profit margin over the last 12 months -- that would equate to roughly $1.3 billion in annual earnings in 2030. Today, the market cap is $12.3 billion, which would mean a P/E of just around 9.5 by 2030 if the market cap did not change (which is an unlikely scenario, but demonstrates that there is potential for the valuation to drop). Even with some shareholder dilution that raises the number of shares outstanding, the stock would be trading at a P/E of around 10 to 12 at the current share price (which is also likely to change). If you believe this rapid growth will continue over the long term, Hims & Hers stock will grow into its valuation. If you have any doubts about this pace of growth, shares should be considered overvalued at the moment. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space was originally published by The Motley Fool
